Patents by Inventor Aru Narendran
Aru Narendran has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11975106Abstract: A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.Type: GrantFiled: March 25, 2021Date of Patent: May 7, 2024Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Aru Narendran, Edward V. Pershing, Dominic Rodrigues, Bruce Horowitz, Eric A. Wachter
-
Patent number: 11974980Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: GrantFiled: June 10, 2021Date of Patent: May 7, 2024Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Patent number: 11938182Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.Type: GrantFiled: September 29, 2021Date of Patent: March 26, 2024Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Aru Narendran, Dominic Rodrigues, Edward V. Pershing, Bruce Horowitz
-
Publication number: 20240082206Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.Type: ApplicationFiled: August 18, 2022Publication date: March 14, 2024Applicants: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Eric A. Wachter, Dominic Rodrigues, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Patent number: 11419844Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.Type: GrantFiled: November 19, 2019Date of Patent: August 23, 2022Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Eric A. Wachter, Dominic Rodrigues, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Publication number: 20220016242Abstract: A method of inducing a Type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the Type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene, and an immunogen to which that response is to be enhanced. A mammalian HX compound-adjuvanted vaccine composition that contains an immunogen present in a vaccine-effective amount along with an adjuvant-effective amount of a halogenated xanthene (HX) compound and one or more excipients present at about 0.001% by weight to 10% by weight of the vaccine composition dissolved or dispersed in a pharmaceutically acceptable diluent.Type: ApplicationFiled: September 29, 2021Publication date: January 20, 2022Applicants: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Aru Narendran, Dominic Rodrigues, Edward V. Pershing, Bruce Horowitz
-
Publication number: 20210308091Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: ApplicationFiled: June 10, 2021Publication date: October 7, 2021Applicants: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. WACHTER, Satbir THAKUR, Lucy SWIFT, Chunfen ZHANG, Mohit JAIN, Aru NARENDRAN
-
Publication number: 20210299083Abstract: A method for treating a viral infection of a mammalian subject that comprises administering a virus-inhibiting amount of a halogenated xanthene, a pharmaceutically acceptable salt, an alkyl ester or amide or aromatic ester or amide derivative thereof as disclosed within, to that mammalian subject. A method of inducing a type I interferon response in a mammalian subject that presents with a microbial infection, cancerous tumor or hematological malignancy that comprises administering an amount of a halogenated xanthene as discussed above, effective to induce the type I interferon response. A method of enhancing a mammalian immunogen-specific immune response that comprises contacting mammalian cells, in vivo or present in a mammalian cell growth supporting medium, with an adjuvant-effective amount of a halogenated xanthene as discussed above, and an immunogen to which that response is to be enhanced.Type: ApplicationFiled: March 25, 2021Publication date: September 30, 2021Applicants: Provectus Pharmatech, Inc., Governors of the University of CalgaryInventors: Aru Narendran, Edward V. Pershing, Dominic Rodrigues, Bruce Horowitz, Eric A. Wachter
-
Publication number: 20210299055Abstract: The present invention contemplates a method of treating a solid cancerous tumor in a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of a halogenated xanthene (HX), the lactone thereof, a pharmaceutically acceptable salt, or a C1-C4 alkyl or aromatic ester thereof (collectively an HX compound) to that mammalian subject, and liquid and solid pharmaceutical compositions for administering the HX compound. In addition, a method of inhibiting the growth of a GI tract carcinoma of a mammalian subject by the oral administration of a solid cancerous tumor-effective amount of an HX compound, as well as solid and liquid pharmaceutical compositions therefor.Type: ApplicationFiled: March 26, 2021Publication date: September 30, 2021Applicants: Provectus Pharmatech, Inc., Governors of the University of CalgaryInventors: Eric A. WACHTER, Dominic RODRIGUES, Edward V. PERSHING, Bruce HOROWITZ, Timothy C. SCOTT, H. Craig DEES, Aru NARENDRAN
-
Publication number: 20210236418Abstract: A method of treating a mammalian subject having hematologic, non-tumorous cancer cells is disclosed. The method comprises the steps of: (A) administering to such a mammalian subject a therapeutically effective amount of a halogenated xanthene, a pharmaceutically acceptable salt or a C1-C4 alkyl ester thereof as a first cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable aqueous medium. The mammalian subject is maintained for a period of time sufficient to induce death of hematologic, non-tumorous cancer cells. A contemplated administration is typically repeated. A contemplated treatment method can also be carried out in conjunction with administration to said mammalian subject of a second therapeutically effective amount of a second, differently-acting cancer cytotoxic agent dissolved or dispersed in a pharmaceutically acceptable medium. The second cancer cytotoxic agent can be a small molecule or an intact antibody or paratope-containing portion thereof.Type: ApplicationFiled: April 16, 2021Publication date: August 5, 2021Applicants: Provectus Pharmatech, Inc,, UTI Limited PartnershipInventors: Aru Narendran, Dominic Rodrigues, Bruce Horowitz, Edward V. Pershing, Eric A. Wachter
-
Patent number: 11058664Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: GrantFiled: May 15, 2019Date of Patent: July 13, 2021Assignees: Provectus Pharmatech, Inc., UTI Limited PartnershipInventors: Jamie Singer, Eric A. Wachter, Satbir Thakur, Lucy Swift, Chunfen Zhang, Mohit Jain, Aru Narendran
-
Publication number: 20190350893Abstract: A method of treating a pediatric cancerous solid tumor in a mammalian subject is disclosed that comprises intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor. Another contemplated method comprises the steps of intralesionally administering an amount of a halogenated xanthene or a pharmaceutically acceptable salt thereof, preferably Rose Bengal disodium, that elicits ablation of tumor cells of the administered tumor and systemically administering a tumor-inhibiting effective amount of a systemic anti-cancer medication that provides synergistic cytotoxicity with the halogenated xanthene. The two administrations can occur concurrently, or one prior to the other.Type: ApplicationFiled: May 15, 2019Publication date: November 21, 2019Applicant: Provectus Pharmatech, Inc.Inventors: Jamie Singer, Eric A. Wachter, Lucy Swift, Chunfen Zhang, Tanya Trippett, Aru Narendran